Prescribing Controlled Substances via Telehealth: The Current Rules

Physicians and nurse practitioners who prescribe Schedule II through V controlled substances through a telehealth encounter are operating under a rulebook that has been rewritten repeatedly since 2020 and remains, as of this writing, temporary rather than permanent. The baseline federal statute, the Ryan Haight Online Pharmacy Consumer Protection Act, generally requires an in-person medical evaluation before a controlled substance may be prescribed, subject to a narrow set of statutory exceptions. Since the COVID-19 public health emergency, the Drug Enforcement Administration and the Department of Health and Human Services have kept that requirement suspended through a series of temporary rules, and prescribers who misread the current posture, or who prescribe outside its conditions, face exposure ranging from registration action to criminal referral. Understanding exactly what is authorized, for how long, and subject to what documentation is now a compliance function in its own right.

The Ryan Haight Baseline and Its Telemedicine Exceptions

Enacted in 2008, the Ryan Haight Act amended the Controlled Substances Act to require that a prescriber conduct at least one in-person medical evaluation of a patient before prescribing a controlled substance, unless the prescription falls within one of seven statutory telemedicine exceptions, such as treatment at a DEA-registered hospital or clinic. A separate, catch-all exception allows the DEA and HHS to jointly designate additional circumstances by regulation as consistent with effective controls against diversion. That catch-all provision is the legal mechanism the agencies have used to authorize the pandemic-era flexibilities that remain in place today.

The Flexibilities Now Run Through December 31, 2026

DEA and HHS have extended the COVID-era telemedicine flexibilities four times since the public health emergency ended, most recently in a joint rule published on December 31, 2025 that keeps the flexibilities in effect through December 31, 2026. Under this extension, a DEA-registered practitioner may prescribe Schedule II through V controlled substances by telehealth without a prior in-person evaluation, and audio-only encounters remain permitted for opioid use disorder treatment with medications such as buprenorphine. The agencies describe the extension as necessary to avoid disrupting care for patients who rely on remote prescribing for behavioral health, substance use disorder, and chronic pain treatment while DEA finalizes permanent rules. Prescribers should treat this as a dated authorization, not a settled feature of federal law.

No telehealth prescriber should assume the current flexibility is permanent, and every practice built on it should have a documented plan for the day it is not renewed.

A Permanent Special Registration Framework Is Still Pending

The Ryan Haight Act separately directs DEA to establish a special registration for telemedicine, a permanent registration category that would let qualified telehealth practitioners prescribe controlled substances remotely under defined conditions, without relying on temporary emergency rules. DEA published a proposed rule in March 2023 addressing this framework, held public listening sessions with practitioners in 2023, and has since represented that it is continuing to draft updated regulations. As of this writing, no final special registration rule has been published, so the temporary extension remains the only lawful basis for most telehealth prescribing of controlled substances without a prior in-person visit.

Suspicious Order Monitoring Obligations Still Apply

The telemedicine flexibilities relax the in-person evaluation requirement. They do not relax any other obligation attached to a DEA registration. Prescribers and the pharmacies that fill their prescriptions remain subject to standard recordkeeping, prescription-monitoring-program checks, and suspicious order monitoring duties designed to flag unusual prescribing volume or geographic dispersion that can indicate diversion. Telehealth platforms generating high volumes of controlled-substance prescriptions across many states are a recognized area of DEA scrutiny. Documentation of the clinical basis for each prescription and the patient relationship is the practitioner's primary defense if that volume draws attention.

Why Early Legal Counsel Is Critical

It is critical that telehealth providers promptly retain healthcare defense counsel upon receiving a DEA subpoena, administrative inspection warrant, or investigative inquiry concerning telehealth controlled-substance prescribing practices. Early legal intervention can protect the provider's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses tied to the flexibility rule in effect at the time of the prescriptions at issue, and allow counsel to communicate with investigators on the provider's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to unnecessary risk.

How Health Law Alliance Can Help

Health Law Alliance advises telehealth prescribers, platforms, and practice groups on structuring controlled-substance prescribing to fit within the current DEA and HHS telemedicine flexibilities, on responding to DEA subpoenas and inspections tied to remote prescribing volume, and on defending practitioners facing registration action or investigation arising from telehealth prescribing patterns. If your practice has received an inquiry or you have questions about how the current rules apply to your prescribing model, contact us for a free, confidential consultation.